Added to YB: 2025-02-05
Pitch date: 2024-12-19
BBIO [bullish]
BridgeBio Pharma, Inc.
+186.14%
current return
Author Info
No bio for this author
Company Info
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Market Cap
$12.8B
Pitch Price
$26.04
Price Target
76.23 (+1%)
Dividend
N/A
EV/EBITDA
-22.19
P/E
-15.87
EV/Sales
39.62
Sector
Biotechnology
Category
growth
BridgeBio Pharma, Inc. - $BBIO
BBIO: FDA-approved Attruby for ATTR-CM, $2B peak sales potential by 2028. 3 key Phase 3 readouts in 2025: encaleret (ADH1), BBP-418 (LGMD2I/R9), infigratinib (achondroplasia). $406M cash, $500M milestone. Risks: clinical failures, competition from Pfizer/Alnylam. Bull case: $76.23/share
Read full article (4 min)